“The topline results from Ascletis’ Phase 3 open-label acne trial in China build additional confidence in the clinical potential of FASN inhibition in acne,” said David Happel, Chief Executive Officer ...

Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.

Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.

HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study ( NCT06248008) evaluating ...

SAN MATEO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

Step into your local drugstore and you’ll come across countless cleansers, serums, lotions and masks all promising the same thing: fewer acne breakouts and clearer, smoother skin. Unfortunately, not ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Sad, but true: Acne doesn’t magically disappear once you graduate high school or turn 21. In fact, more ...

This can have a huge impact on your circulation, and it can cause symptoms like numbness and tingling in your hands and feet, headache, and vision changes. Even worse, severe cases are associated with ...

Sad, but true: Acne doesn’t magically disappear once you graduate high school or turn 21. In fact, more than 25% of women and 12% of men in their forties regularly battle breakouts. And with just 10% ...